The Maurice lab is proud to announce that Laigo Bio has launched their website!
Madelon is the co-founder and scientific lead of this startup that aims to develop SureTACs technology. Laigo Bio sprouted from the research of the Maurice lab, focused on degradation of target proteins at the cell surface, via redirection of transmembrane E3 ligases. How the induced proximity between target and E3 leads to ubiquitination, endocytosis and degradation of the target is actively being researched within the group.
Laigo Bio is dedicated to developing first-in-class therapeutics for patients with severe or life-threatening diseases by removing and degrading any cell surface targets with precision. Visit the website to learn how Laigo Bio is pioneering life-changing solutions in biotechnology: www.laigobio.com.